

1 Elucidating the combined toxicity of aflatoxin B1 and
2 fumonisin B1 on HepG2 cells based on respirometry
3 and transcriptome analyses

4 Xiangrong Chen ^{1*}, Mohamed F. Abdallah ^{1,2}, Charlotte Grootaert ¹, Filip Van Nieuwerburgh ³,
5 Andreja Rajkovic ^{1*}

6

7 ¹ Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University,
8 Ghent, Belgium.

9 ² Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Assiut University, Assiut
10 71515, Egypt.

11 ³ Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent,
12 Belgium.

13

14

15

16

17

18 * Corresponding author: xiangrong.chen@ugent.be (+ 32 4 849 01 379) and andreja.rajkovic@ugent.be (+ 32
19 9 264 99 04), Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent
20 University, Ghent, Belgium.

21 **Abstract**

22 Aflatoxin B1 (AFB1) and fumonisin B1 (FB1) are two toxic mycotoxins widely found in food
23 contaminants, and known for their hepatotoxicity in human. However, their combined toxicity still
24 needs to be deeply investigated especially for their harmful effect. Therefore, the current work
25 aimed at investigating the (combined) effect of AFB1 and FB1 on mitochondrial and glycolytic activity
26 of HepG2 cell line, a well-recognized *in vitro* model system to study liver cell function. In our previous
27 work, we studied the impact of a short term exposure to different doses of AFB1, FB1, and their
28 binary mixture (MIX) on the bioenergetic status of HepG2 cells. Seahorse respirometry analysis
29 revealed that the co-exposure, especially at high doses (8 µg/mL for AFB1 and 160 µg/mL for FB1), is
30 more toxic as a result of more inhibition of all parameters of mitochondrial respiration. RNA
31 transcriptome sequencing showed that the p53 signaling pathway, which is a major orchestrator of
32 mitochondrial apoptosis, was differentially expressed. Moreover, the co-exposure has significantly
33 downregulated Cx I, Cx II, Cx III, and Cx IV genes, which represent the onset of the suppressed
34 mitochondrial respiration in HepG2 cells. It was found that FB1 is contributed more to the MIX
35 effects than AFB1.

36 **Environmental Implication**

37 Aflatoxin B1 (AFB1) and fumonisin B1 (FB1) are two main mycotoxins that frequently (co-
38)contaminate maize and maize-based ingredients in several parts of the world. Both toxins are well-
39 known for their hepatotoxicity in humans as the liver is their main target organ. However, the
40 combined toxicity of AFB1 and FB1 still needs to be deeply investigated especially for their effect on
41 cellular respiration. In this study, we proved that a binary mixture of AFB1 and FB1 is more toxic on
42 mitochondrial respiration, and disrupted the p53 signaling pathway to induce apoptosis, which
43 promised a novel insight of hazardous materials-induced hepatic damage.

44 **Abbreviations**

45 AFB1, Aflatoxin B1; FB1, fumonisin B1; MIX, their binary mixture; CON, control; HepG2, human
46 hepatocellular carcinoma; IARC, International Agency for Research on Cancer; ATP, adenosine
47 triphosphate; ROS, reactive oxygen species; DMEM, Dulbecco's modified Eagle's medium; NEAA,
48 non-essential amino acids; FBS, Fetal Bovine Serum; PBS, Phosphate buffer saline; MTT, tetrazolium
49 salt, MMP, mitochondrial membrane potential; OXPHOS, oxidative phosphorylation; ECAR,
50 extracellular acidification rate; OCR, oxygen consumption rate; DEGs, differentially expressed genes;
51 FC, fold change; FDR, false discovery rate; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes
52 and Genomes; ETC, electron transport chain; IMM, the inner mitochondrial membrane; AFBO, AFB1-

53 exo28,9-epoxide; PPP, pentose phosphate pathway; G6P, glucose-6-phosphate; G6PD, glucose-6-
54 phosphate dehydrogenase.

55

56 **Keywords:** aflatoxin B1, fumonisin B1, bioenergetics, seahorse analysis, significant interaction, p53,
57 apoptosis, transcriptomics

58 **1. Introduction**

59 Recent advances in mycotoxin analysis showed that the co-occurrence of several mycotoxins in a
60 single food or crop is more common than the occurrence of a single mycotoxin (Palumbo et al. 2020).
61 However, most of the available knowledge regarding the toxicity of mycotoxins in human is limited to
62 the study of a single mycotoxin, and little is known about the interaction of a mycotoxin mixture in
63 the biological systems. Such interaction could be additive, antagonistic, or synergistic, which may
64 alter the toxic outcomes (Alam et al. 2022). Currently, the number of mycotoxins in food is expected
65 to be much more than 400, varying in their chemical structures and hence their toxicities (Decler et
66 al. 2018; Palumbo et al. 2020; Wu et al. 2014). In the present work, we have selected two mycotoxins
67 (aflatoxin B1 and fumonisin B1) which have been found to co-occur in different food samples,
68 especially maize, collected from Africa, America, Asia, and Europe (Chen et al. 2021; Du et al. 2017;
69 Palumbo et al. 2020). Besides, aflatoxin B1 (AFB1) and fumonisin B1 (FB1) are considered among the
70 most toxic fungal secondary metabolites. The International Agency for Research on Cancer (IARC)
71 classified AFB1 as a group 1 carcinogen due to the sufficient evidence of causing liver cancer in
72 humans, while FB1 is classified as a class 2B carcinogen as the evidence of causing cancer is limited
73 (IARC 2012). Other toxic effects of AFB1 and FB1 also include hepatotoxicity, nephrotoxicity, and
74 embryotoxicity, immunotoxicity (Chen et al. 2022).

75 Mitochondria are critical cellular organelles that make adenosine triphosphate (ATP) appropriately in
76 response to the cellular energy demands, hence known as the powerhouse of the cell (Vyas et al.
77 2016). Besides, these organelles perform many roles, including the generation of reactive oxygen
78 species (ROS) and regulation of cell signaling and cell death. Due to their highly abundance in
79 hepatocytes, they have been recognized as a key mediator in hepatotoxicity. Such toxicity could be
80 induced by the loss of mitochondrial function creating a mitochondrial metabolic gridlock, such as
81 the inhibition of mitochondrial respiration (Prakash et al. 2022). The *in vitro* hepatotoxicity of AFB1
82 and FB1 has been reported in many studies using the HepG2 cells as the preferred liver model (Abdul
83 and Chuturgoon 2021; Chen et al. 2022; Singto et al. 2020). Oxidative stress, inflammation, and
84 mitochondrial dysfunction by targeting ROS, DNA, p53, and other signaling pathways have been
85 documented as toxic mechanism of AFB1 (Li et al. 2022). Similarly, FB1 induced hepatotoxicity by
86 inhibiting sphingolipids biosynthesis and triggering massive production of ROS have been also
87 reported (Sheik Abdul and Marnewick 2020).

88 Based on these studies, it was found that both AFB1 and FB1 could damage mitochondrial function to
89 cause hepatotoxicity. Currently, there are few reports on the use of *in vitro* systems for the analysis
90 of AFB1 and FB1 mixtures, especially the effect on mitochondria. Therefore, the aim of the study

91 reported here was to evaluate the interaction of AFB1 and FB1 in HepG2 cells. We investigated the
92 impact of AFB1 and FB1 as well as their combination (binary mixture) on the mitochondrial and
93 glycolytic activities using seahorse extra-cellular flux analysis that decipher bioenergetic phenotype,
94 and by transcriptome analysis using RNA (Illumina) sequencing to better understand functional
95 biology underlying observed phenotypic mitochondrial function signatures.

96 **2. Materials and Methods**

97 **2.1. Chemical reagents**

98 The mycotoxin FB1 (Cas. No. 116355-83-0; 99 % purity) was obtained from Sigma (USA), while AFB1
99 (Cas. ALX-630-093-M005; >98 % purity) was purchased from Enzo Life Sciences (Belgium). Stock
100 solutions (10 mg/mL) of FB1 and AFB1 were prepared in dimethyl sulfoxide (DMSO) at stored at -20 °C,
101 while working solutions were freshly prepared in a cell growth medium at different concentrations
102 and combinations of FB1 and AFB1 (**Table 1**). Dulbecco's modified Eagle's medium (DMEM)
103 supplemented with GlutaMAX™, a mixture of penicillin/streptomycin, and non-essential amino acids
104 (NEAA) were all purchased from Thermo Life Technologies (Merelbeke, Belgium). Fetal Bovine Serum
105 (FBS) was supplied from VWR (Leuven, Belgium). Trypsin-EDTA 0.05 % from Thermo Fisher Scientific
106 (Merelbeke, Belgium). Phosphate buffer saline (PBS) with or without Ca²⁺ and Mg²⁺ were obtained
107 from Westburg (Leusden, Netherlands).

108 **2.2. Cell culture and mycotoxin exposure**

109 HepG2 (human hepatocellular carcinoma) cells were obtained from the American Type Culture
110 Collection (ATCC, Manassas, VA, USA) and cultured in DMEM medium (Gibco™, GlutaMAX™)
111 containing 4.5 g/LD-glucose and pyruvate, and externally supplemented with FBS (10 %), mixture of
112 penicillin/streptomycin (1 %) and NEAA (1 %). Cells were grown in T-75 (75 cm²) polystyrene cell
113 culture flasks (Thermo Life Technologies, Merelbeke, Belgium) in a humidified chamber with 10 %
114 CO₂ at 37 °C and 95 % air atmosphere at constant humidity. The growth culture medium was changed
115 every 2-3 days and cell morphology was regularly checked by visual inspection with phase-contrast
116 microscopy (Leica DMIC, Leica Microsystem GmbH, Wetzlar, Germany). When the degree of
117 confluence reaches approximately 80 % (every 4-6 days), cells were subcultured to maintain the
118 rapid growth of the cells. Consequently, HepG2 cells were gently rinsed with prewarmed PBS for a
119 few seconds, detached from the flask with 4 mL of pre-warmed trypsin-EDTA 0.05 % for 2-3 min, and
120 seeded in a new T-75 flask (ratio 1:5).

121 HepG2 cells were exposed to three different concentrations of AFB1 (0.5, 2, and 8 µg/mL) and FB1
122 (10, 40, and 160 µg/mL) to mimic three different scenarios of exposure (low, middle and high).

123 Furthermore, we applied three combinations (low-low, middle-middle, and high-high) as a binary
124 mixture (MIX) of AFB1 and FB1 (**Table 1**). These concentrations were applied based on the estimated
125 exposure data derived from measuring the average of urinary biomarkers of AFB1 (0.5 µg/mL) and
126 FB1(10 µg/mL) in humans, which were considered here in the current work as low exposure scenario
127 (Chen et al. 2022; Meneely et al. 2018). This level was increased four folds to have a middle exposure
128 scenario and eight folds as high exposure scenario to investigate the potential toxicity.

129 **Table 1.** Different concentrations of AFB1 and FB1 as well as their combinations used in the current work.

Concentrations	AFB1 (µg/mL)	FB1 (µg/mL)	MIX	
			AFB1 (µg/mL)	FB1 (µg/mL)
Low	0.5	10	0.5	10
Middle	2	40	2	40
High	8	160	8	160

130

131 **2.3. Cytotoxicity endpoint measurements (MTT, ROS, and MMP)**

132 The tetrazolium salt (MTT) (Life Technologies Corporation, Eugene, OR, USA) assay, which is based on
133 the cellular conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide into
134 formazan, was performed to determine the cell viability after the exposure to AFB1 and FB1 (Chen et
135 al. 2022). Briefly, HepG2 cells were seeded before the treatment in 96-well plates at a density of
136 20,000 per well for 24 h at 37 °C in a sterilized incubator with a humidified atmosphere of 10 % CO₂ to
137 allow cell adhesion. FB1 and AFB1 were diluted with DMEM at different concentrations and 200 µL
138 were added. The applied toxic doses of AFB1, FB1, and their mixture (MIX) are shown in **Table 1**. MTT
139 was measured using SpectraMax™ Microplate Reader (Molecular Devices, Berkshire, UK), as
140 described in the literature (Chen et al., 2022). Levels of ROS and MMP (mitochondrial membrane
141 potential) were measured to reflect the toxic effect of AFB1 and FB1 on HepG2 cells. ROS generation
142 and MMP were measured using a fluorescent probe (2',7'-dichlorodihydrofluorescein diacetate
143 (DCFH-DA)) (Sigma-Aldrich) and the fluorescent probe Tetramethylrhodamine ethyl ester (TMRE)
144 (Sigma-Aldrich), respectively, as described in literature (Chen et al., 2022). Cells were seeded at a
145 density of 50,000 per well in a black 96-well plate for 24 h, and incubated with FB1 and AFB1 at
146 different concentrations for another 24 h (**Table 1**). ROS and MMP were measured using
147 SpectraMax™ Microplate Reader (Molecular Devices, Berkshire, UK), and the exact excitation and
148 emission wavelengths were followed as described in the literature (Chen et al., 2022).

149 **2.4. HepG2 bioenergetic analysis using Seahorse Extracellular Flux Analyzer (total ATP**
150 **production, glycolysis, and mitochondrial respiration)**

151 The Seahorse XF96 Analyzer instrument (Agilent Seahorse Bioscience, CA, USA), and the related
152 consumables (plates, cartridges, and inhibitor kits) were used to measure total ATP production,
153 glycolysis, and mitochondrial respiration according to the manufacture instructions. In brief, the
154 assay medium was prepared by supplementing Seahorse XF Base medium (pH 7.4) with a specific
155 combination of 10 mM glucose (100X stock, Agilent), 1 mM pyruvate (100X stock, Agilent), and 2 mM
156 L-glutamine (Sigma). At first, cells were harvested from the T-75 flasks and seeded into a Seahorse
157 96-well XF Cell Culture microplate (Agilent Seahorse Bioscience, CA, USA) in 80 μ L of the culture
158 medium at a density of 20,000/well. The optimal cell density was previously determined and is part
159 of laboratory SOPs for different cell types. The cells were incubated at 37°C in a pre-sterilized
160 incubator with atmosphere containing 10 % CO₂ and 95 % constant humidity for 24 h. Next, HepG2
161 cells were treated with the same doses of AFB1, FB1, and MIX as shown in **Table 1**.

162 In parallel, a Seahorse XF Sensor Cartridge was hydrated one day before running the XF Assay by
163 filling each well of the XF Utility Plate with 200 μ L of sterile water. On the day of analysis, the sterile
164 water was replaced by seahorse XF calibrant solution. The hydrated cartridge was for 24h
165 maintained in an incubator at 37 °C without CO₂ to remove CO₂ from the media that may interfere
166 with measurements by altering the pH. Cells washing and measurement cycles were performed
167 following our established protocol (Chen et al., 2022). Preformulated and optimized Seahorse specific
168 real-time ATP rate assay kit, glycolysis stress test kit, and Mito stress test kit (all from Agilent) were
169 used to measure total ATP production, glycolysis, and mitochondrial respiration, respectively. The
170 accurate concentrations and volumes for each inhibiting compound used in each kit are described in
171 **Table 2**. Seahorse Wave Controller Software version 2.6.3 (Agilent Seahorse Bioscience, CA, USA) was
172 used to operate and control the Seahorse XF96 Analyzer instrument. After the measurements were
173 done, data were exported for processing and analysis (see **Data processing and analysis**).
174 Normalization was performed by fixing the cells using sulforhodamine B dye (Sigma-Aldrich, Co., St.
175 Louis, MO, USA) as described before (Chen et al., 2022).

176

177 **Table 2.** Required concentrations and volumes of each inhibitor per assay.

Kit		Agilent seahorse XF real-time ATP rate assay kit	Agilent seahorse XF glycolysis test kit	Agilent seahorse XF stress test kit
	Compound (S)	Oligomycin	Glucose	Oligomycin
Port A	Concentration (μM)	1.5	10000	1
	Volume (μL)	20	20	20
	Compound (S)	Rotenone Antimycin A	Oligomycin	FCCP
Port B	Concentration (μM)	0.5	1	0.25
	Volume (μL)	22	22	22
	Compound (S)	-	2-Deoxy-D-glucose (2-DG)	Rotenone Antimycin A
Port C	Concentration (μM)	-	50000	0.5
	Volume (μL)	-	25	25

178 **2.5. Transcriptome analysis (RNA isolation, processing and sequencing)**

179 The complete set of RNA transcripts of HepG2 was studied at high concentrations of AFB1 (8 $\mu\text{g}/\text{mL}$)
180 and FB1 (160 $\mu\text{g}/\text{mL}$) as well as their binary combination (high MIX) as these concentrations and
181 combination induced toxic effect on mitochondria according the seahorse extra-cellular flux analysis.
182 Transcriptome analysis including RNA isolation, processing and sequencing was conducted according
183 to previously established protocols (Degroote et al. 2021). The experiment was repeated
184 independently five times with identical conditions to provide at least five biological replicates for
185 each time point and treatment. In summary, HepG2 cells were cultivated as previously mentioned
186 but in six well-plates while keeping the same cell density. After 24 h of exposure to the mycotoxins
187 under study, the growth media were completely removed. To harvest the cells, PBS (one mL) of was
188 added to each well and the adherent cells were collected by cell scrapers (Greiner Bio-One, Vilvoorde,
189 Belgium) and transferred into two mL Eppendorf tubes. After centrifugation for two min at 8000 g,
190 the supernatant was discarded and the RNA extraction was performed with the RNeasy® Mini Kit
191 (Qiagen, Hilden, Germany) following the instruction handbook. In short, 600 μL lysis Buffer RLT was
192 applied to the pellets, 600 μL 70 % ethanol was added, and the total volume was transferred to an
193 RNeasy Mini spin column placed in a collection tube to be centrifuged at 8000 g for 15 sec. The flow
194 through is discarded, and the column is washed with Buffer RW1 and Buffer RPE, before eluting the

195 RNA in 40 μ L RNase-free water. A Bioanalyzer RNA 6000 Nano assay (Agilent Technologies, CA, USA)
196 was used to measure RNA quality, providing a RIN (RNA Integrity Number) value. All the samples had
197 an RNA integrity number (RIN) value above nine. RNA from each sample was quantified using the
198 'Quant-it ribogreen RNA assay' (Life Technologies, Grand Island, NE, USA) and 500 ng RNA was used
199 to prepare an Illumina sequencing library using the QuantSeq 30 mRNA-Seq Library Prep Kit (Lexogen,
200 Vienna, Austria) according to manufacturer's protocol with 14 enrichment polymerase chain reaction
201 (PCR) cycles. An average of $9.0 \times 10^6 \pm 1.8 \times 10^6$ and $11.6 \times 10^6 \pm 1.0 \times 10^6$ reads were generated.


202 **2.6. Data processing and analysis**

203 Excel© for Microsoft Office 365 (Microsoft Corporation, Redmond, USA) was used to normalize all
204 data, except for transcriptome data. SPSS software package (SPSS Statistics 27, USA) was used for the
205 statistical evaluation. Comparisons between the untreated control and different FB1 and AFB1
206 treatments within each mitochondrial parameter (basal respiration, maximal respiration, ATP
207 production, proton leak, non-mitochondrial respiration, and spare respiratory capacity) were
208 performed using a one-way analysis of variance (ANOVA) test followed by Tukey HSD multiple-
209 comparison test as a post hoc analysis to identify the sources of detected significance ($p < 0.05$). Data
210 are presented as mean \pm standard deviation (SD). Analysis for differential gene expression was
211 performed using the edgeR's (40) quasi-likelihood method between 2 conditions, only including
212 genes that were expressed at a counts-per-million (cpm) above 1 in at least 5 samples. Genes were
213 considered significantly differential if they had a false discovery rate (FDR) < 0.05 , as well as a fold
214 change of at least 2. Gene set enrichment analysis (GSEA) was performed using the GAGE R package,
215 based on the Kyoto encyclopedia of genes and genomes (KEGG) pathways provided by this package.
216 Genes and KEGG pathways of interest were selected based on their impact on diabetes pathology,
217 hepatic fat synthesis, and energy metabolism. Significance thresholds $|\log(\text{FC})| > 1$ and $\text{FDR} < 0.05$
218 were set in performing heatmaps; $|\log_2\text{FC}| = 1$ and $P = 0.05$ were set in performing volcano plots
219 based on edgeR analysis. Finally, the effects of mycotoxins on pathways were also calculated and
220 displayed in the heat map. The heat map expresses the magnitude enrichment analysis was
221 performed using the GSEA software (v4.2.3) and Molecular Signatures Database (MSigDB) Hallmark
222 Gene Signatures. Gene sets were considered significantly enriched when q-value $\text{FDR} < 0.05$, and
223 normalized enrichment scores (NES) were used for further calculations of e.g. z-scores.


224 3. Results

225 3.1. Cytotoxicity of AFB1, FB1, and their combination after measuring MTT, ROS, and MMP

226 Treatment of HepG2 cells with either AFB1 or FB1 or their binary combination (MIX) resulted in a
227 concentration-dependent increase in intracellular ROS, and induction of MMP disruption and
228 therefore cell damage. As shown in **Figure 1**, a combination of AFB1 and FB1 at low concentration
229 (low MIX) had no inhibitory effect on cellular viability in comparison to the individual effect imposed
230 by either AFB1 or FB1 treatment. While a binary mixture of AFB1 and FB1 at middle and high
231 concentrations (middle and high MIX) led to a significant loss of cell viability, which was between 9-
232 24 % and 3-7 % higher compared to the loss of cell viability caused by AFB1 and FB1 alone,
233 respectively. Significant increases in intracellular ROS levels were detected in case of exposure to
234 AFB1 (high concentration) and FB1 (middle and high concentration) as well as the three levels of
235 combinations (low, middle, and high MIX). The increase in ROS levels with a combination (MIX) was
236 between 5-19 % more than the ROS levels with AFB1 and between 18-29 % higher than those levels
237 detected with FB1. As depicted in **Figure 1**, the MMP disruption in HepG2 cells exposed to high
238 concentrations of AFB1 (8 µg/mL) and FB1 (160 µg/mL) as well as their binary combination (high MIX)
239 showed a slight but significant ($p<0.05$) dose-dependent MMP decrease. This decrease in MMP levels
240 was about 12% for AFB1 and FB1 alone, and about 16% for the MIX, compared to the MMP from the
241 untreated control cells. These results demonstrate that the applied doses of AFB1 and FB1 reduce
242 cell viability and MMP and induce the generation of more intracellular ROS in HepG2 cells. By
243 comparing the toxic impact of AFB1 or FB1 and their MIX in each exposure scenario (low, middle, and
244 high), the binary combination (MIX) shows a trend to stronger effects in all cytotoxicity endpoints,
245 although this was not always statistically different than the toxic effect caused by exposure to the
246 individual AFB1 or FB1.



247



248

249


250 **Figure 1.** Effect of FB1, AFB1, and MIX on cell viability (MTT), intracellular reactive oxygen species (ROS), and mitochondrial
251 membrane permeability (MMP) in HepG2 cells after 24 h exposure. Data (at least three well-replicates) are expressed as
252 mean \pm standard deviation. Significance compared to the mycotoxin-free condition is labeled by *: $p < 0.05$ according to a
253 one-way ANOVA with Dunnett's post hoc test. Significance compared to the same mycotoxin per concentration is labeled
254 by #: $p < 0.05$ according to a one-way ANOVA with Tukey HSD multiple-comparison post hoc test.

255 **3.2. Impact of AFB1, FB1 and their combination on HepG2 bioenergetics**

256 **3.2.1 Total ATP production**

257 To investigate the impact of AFB1 and FB1 as well as their combination on the total ATP production
258 derived from glycolysis and mitochondrial respiration via oxidative phosphorylation (OXPHOS), the
259 Seahorse XF Real-Time ATP Rate assay was used. As depicted in **Figure 2**, the total ATP production
260 was inhibited in the three scenarios of exposure (low, middle, and high) either after individual
261 treatment of AFB1 or FB1 or their binary combination (MIX) treatment in a concentration-dependent
262 manner, which were statistically significant ($p < 0.05$). Interestingly, the exposure to AFB1 or FB1 or
263 their combination (MIX) at the highest levels of exposure significantly shifted the balance or the
264 contribution ratio of glycolysis versus OXPHOS for the total ATP yield to be more relying on the ATP

265 generation via OXPHOS. After the exposure to MIX (low and middle level), the inhibition of the ATP
266 production is situated between the effects of the single toxin treatments, thereby suggesting
267 interactions at the energy-providing pathway level. In contrast, upon exposure to high MIX, it
268 showed the strongest decrease (but not significant compared the individual exposure to toxins) in
269 total ATP production, and caused a significant shift compared to the AFB1 and FB1 condition(s) from
270 glycolytic to mitochondrial ATP production of 34 % that is the difference of OXPHOS ATP (67 %) and
271 glycolysis (33 %). In various cancer cells such as HepG2 cells, glycolysis is enhanced and OXPHOS
272 capacity is diminished. In the current work, the observed shifts in the contribution ratio between
273 glycolysis and OXPHOS for the total ATP provide an unfavorable environment for cell growth (Zheng
274 2012).




275

276 **Figure 2.** Effect of AFB1, FB1, and MIX on mitochondrial and glycolytic ATP production rates in HepG2 cells after 24 h
277 exposure. Data (at least four technical replicates) are expressed as mean \pm standard deviation. *: $p < 0.05$ indicates
278 significantly different results compared to the untreated condition control by one-way ANOVA with Dunnett's post hoc test.

279 **3.2.2. Glycolytic pathway for energy production in HepG2 cells**

280 Basically, the glucose is converted into pyruvate (referred to as glycolysis) and then converted to
281 lactate in the cytoplasm or CO_2 and water in the mitochondria. The conversion of glucose to pyruvate,
282 and subsequently lactate, results in net production and extrusion of protons into the extracellular
283 medium. This extrusion of protons results in the acidification of the medium surrounding the cell.
284 The extracellular acidification rate (ECAR) is related to the lactate secretion, which in turn is directly
285 related to the glycolytic flux. Therefore, the glycolytic rate was measured as ECAR by the glycolytic
286 rate using the Seahorse XF96 Analyzer. In the current work, the glycolytic activity of HepG2 cells was
287 assessed following real-time changes in ECAR levels. After a 24 h treatment with either AFB1 or FB1
288 or their binary combination (MIX), there was a reduction in the glycolysis, glycolytic reserve, and

289 glycolytic capacity ($p < 0.05$), except for the low exposure level (10 $\mu\text{g}/\text{mL}$) of FB1 treatment (**Figure**
 290 **3**). When HepG2 cells were exposed to a combination of the two toxins (high MIX), the levels of
 291 glycolysis, glycolytic reserve, and glycolytic capacity were decreased in comparison to the individual
 292 treatment of AFB1 or FB1, however, these decreases were not statistically significant. These results
 293 demonstrate that high MIX (8 $\mu\text{g}/\text{mL}$ for AFB1 and 160 $\mu\text{g}/\text{mL}$ for FB1) might have a more disruptive
 294 effect on the glycolysis. However, the significant interaction of AFB1 and FB1 on the negative effect
 295 on glycolytic activity was not observed.




296

297 **Figure 3.** Effect of AFB1, FB1, and MIX on extracellular acidification rate (ECAR) (left) and different glycolytic parameters
 298 (right) in HepG2 cells after 24 h exposure. Data (at least four technical replicates) are expressed as mean \pm standard
 299 deviation. Mean values with different symbols (*: compared to control) within each glycolytic parameter indicate significant
 300 differences ($p < 0.05$) among different treatments according to one way ANOVA test followed by the Tukey HSD multiple-
 301 comparison test as a post-doc analysis.

302 **3.2.3. Mitochondrial respiration pathway for energy production in HepG2 cells**

303 In parallel, the effect of AFB1 and FB1 mixture on the ability of HepG2 cell to regulate mitochondrial
304 respiration in comparison to the single exposure to AFB1 or FB1 was examined. In this regard,
305 Oxygen Consumption Rate (OCR) is used as an indicator of mitochondrial respiration. An inhibition
306 was observed in the mitochondrial activity of HepG2 cells after the exposure to three levels (low,
307 middle, and high) of AFB1 or FB1 or their combination (MIX) (**Figure 4**). Especially the exposure to
308 AFB1 or FB1 or their binary combination (MIX) at the high levels of exposure decreased the basal
309 respiration, maximal respiration, ATP production, and proton leak ($p < 0.05$), and increased the spare
310 respiratory capacity ($p < 0.05$) compared to untreated control. Moreover, when HepG2 cells were
311 exposed to a combination of the two toxins (high MIX), all these mitochondrial parameters were
312 significantly decreased in comparison to the individual treatment of high AFB1 (8 $\mu\text{g}/\text{mL}$) or high FB1
313 (160 $\mu\text{g}/\text{mL}$). However, these significant decreases were not always present in the other two
314 exposure scenarios (low and middle) between comparisons of the individually toxic impact of AFB1
315 or FB1 with their binary combination (MIX). These results demonstrate that high MIX (8 $\mu\text{g}/\text{mL}$ for
316 AFB1 and 160 $\mu\text{g}/\text{mL}$ for FB1) might cause more disruption of the mitochondrial metabolism, and a
317 significant changes in mitochondrial dysfunction seem to be attributed to the toxic outcome of the
318 interaction between AFB1 and FB1.



319


320 **Figure 4.** Effect of AFB1, FB1, and MIX on oxygen consumption rate (OCR) (left) and different mitochondrial parameters
 321 (right) in HepG2 cells after 24 h exposure. Data (at least four technical replicates) are expressed as mean \pm standard
 322 deviation. Mean values with different symbols (*: compared to control; #: compared to MIX) within each mitochondrial
 323 parameter indicate significant differences ($p < 0.05$) among different treatments according to the one-way ANOVA test
 324 followed by the Tukey HSD multiple-comparison test as a post hoc analysis.

325 **3.3. Impact of AFB1, FB1 and their combination on HepG2 transcriptomic responses**

326 **3.3.1. Expression profiles of mRNAs in experimental groups**

327 A total number of 29744 genes were detected after the exposure of HepG2 cells to either AFB1 (8
 328 $\mu\text{g}/\text{mL}$) or FB1 (160 $\mu\text{g}/\text{mL}$) or their binary combination (MIX: 8 $\mu\text{g}/\text{mL}$ for AFB1 and 160 $\mu\text{g}/\text{mL}$ for
 329 FB1). A heatmap based on color key for the gene clustering is depicted in **Figure 5a**. Replicas from the
 330 same condition always cluster together, thereby generating four clusters according to HepG2 cell
 331 treatments. Regardless the treatment condition, the untreated control group had a distinct
 332 separation. The FB1 and MIX groups clustered together, thereby indicating a strong contribution of
 333 FB1 to the overall MIX effect compared to AFB1 alone, which yielded a clear distinct expression

334 pattern compared to the other conditions (**Figure 5a**). Volcano plot based on the log Fold Change (FC)
335 and the False Discovery Rate (FDR) of each tested gene is shown in **Figure 5b**. The cutoff value for the
336 FDR was adjusted at 0.05, while $\log_2FC < -1$ for the downregulated genes and $\log_2FC > 1$ for
337 upregulated genes were set to check the top significant genes. In comparison to the MIX group, AFB1
338 treated samples showed a large number of genes that downregulated (in the blue color) and
339 upregulated (in red color). On the other hand, FB1 treated group had much less fold changes in the
340 expressed gene in comparison to the MIX group (i.e. less number of the significant genes). The Venn
341 diagrams in **Figure 5c** show the differential genes that are either up- or downregulated between the
342 treatments. Compared to the untreated control (CON) scores, AFB1 resulted in 2336 different
343 differentially expressed genes (DEGs), of which 558 DEGs are identical to those differentially
344 expressed upon MIX treatment, which contained 312 upregulated DEGs and 246 downregulated
345 DEGs. Similarly, compared to CON, FB1 treatment resulted in 2321 DEGs of which 1318 DEGs were
346 identical to those differentially expressed upon MIX treatment, including 609 upregulated DEGs and
347 709 downregulated DEGs. Compared to the MIX condition, only 72 upregulated and 10
348 downregulated DEGs were shared between AFB1 and FB1, thereby confirming the different mode-of-
349 action of both mycotoxins. In these Venn diagrams, it is also clearly visible that the single AFB1
350 condition is more different than the FB1, and thus contributes less to the MIX effects.




351

352 **Figure 5.** Differentially expressed genes in experimental groups. (a) Heatmap for outcoming of the weighted gene co-expression network analysis (WGCNA) on all conditions; (b) Volcano plot
 353 based on the fold change and the false discovery rate (FDR) of each tested gene. The cutoff for FDR was set at 0.05. Blue dots represent downregulated genes ($\log_2\text{FC} < -1$), red dots represent
 354 upregulated genes ($\log_2\text{FC} > 1$), black dots represent the genes that did not pass the thresholds for FDR and Log Fold Change; (c) Venn diagrams of the overlapping and differentially
 355 expressed genes

356 **3.3.2. Kyoto encyclopedia of genes and genomes (KEGG) analysis-p53 pathway**

357 Pathway analysis based on Gene Ontology (GO) (50 pathways) and Kyoto Encyclopedia of Genes and
358 Genomes (KEGG) (338 pathways) databases led to the discovery of significantly enriched pathways
359 upon AFB1 and FB1 treatment versus a combination of the two mycotoxins (MIX) treatment. Upon
360 KEGG analysis, 6 significantly different KEGG pathways were identified when comparing FB1 and MIX
361 (Herpes simplex virus 1 infection, Ribosome, Fanconi anemia pathway, Amyotrophic lateral sclerosis,
362 Cell cycle, and p53 signaling pathway), whereas no differential pathways were identified between
363 AFB1 and MIX. Overall these pathways, p53 signaling pathway is actively involved in bioenergetics
364 and cell death. In **Figure 6**, it was shown the p53 signaling pathway genes that are differentially
365 expressed with the comparison of FB1 and MIX. In this signaling pathway, MIX significantly
366 downregulated Fas, DR5, Nora, PUMA, PIGs, Pag608 and upregulated p53, Bcl-xL, and Scotin.
367 Subsequently, genes with mitochondrial and hence bioenergetic impact were significantly
368 downregulated by MIX, including Cx I, Cx II, Cx III, Cx IV, PINK, and Bad. Cx I, Cx II, Cx III, and Cx IV are
369 major mitochondria respiratory complexes in the electron transport chain (ETC), is linked to the CytC
370 inducing apoptosis. As a result, further downregulated CytC, Apaf-a, CASP9, and CASP3, which may
371 explain the cell death, possibly mediated by apoptosis in HepG2 cells. Because these differences
372 were seen at the complete pathway level, there is a strong evidence that they pinpoint the major
373 mode of action explaining the previous results.




374
375
376

Figure 6. A pathway diagram of the p53 pathway of FB1-MIX as annotated by the Kyoto Encyclopedia of Genes and Genomes (KEGG). The color in which the genes are marked correlates to the response value of the comparison between fumonisin FB1 (FB1) and the AFB1-FB1 mixture (MIX).

377 **3.3.3. Gene ontology (GO) analysis**

378 Gene Set Enrichment Analysis (GSEA) using the Hallmark gene sets showed that AFB1, FB1, and their
379 binary combination (MIX) treatments affect key cellular processes. Key regulatory pathways (i.e.
380 hypoxia, unfolded protein response, and p53 pathway), metabolic mechanisms (i.e. cholesterol
381 homeostasis, OXPHOS, and glycolysis), and immune responses (i.e. TNF- α signaling via NF- κ B,
382 mTORC1 signaling, IFN- γ , IFN- α , and inflammatory response) were enriched in AFB1, FB1, and MIX
383 versus CON, and in AFB1 and FB1 versus MIX. A heat map of z-scores of the Normalized Enrichment
384 Score (NES) for each hallmark represents the differences in the enrichment of each hallmark
385 between the pre-treatments (**Figure 7**). Upon GO analysis, seven differential pathways were
386 identified when comparing FB1 and MIX (UV response DN, E2F targets, G2M checkpoint, p53
387 pathway, MYC targets V1, DNA repair, and mTORC1 signaling), and 4 differential pathways when
388 comparing AFB1 and MIX (p53 pathway, MYC targets V2, DNA repair, and UV response DN). It was
389 observed that AFB1 and FB1 mainly disrupted cell proliferation and as a result, MIX significantly
390 altered proliferation genes compared to CON/AFB1/FB1. In addition, AFB1 also showed significant
391 induction of DNA damage.



392

393

394

395

Figure 7. Heatmap of Z-scores of the MSigDB hallmark gene sets using Gene Set Enrichment Analysis (GSEA), showing the significantly enriched gene sets (FDR<0.05) across the treatments according to a pairwise comparison. Non-significant (n.s.) differences are marked by X.

396 **4. Discussion**

397 The current study aimed at identifying the short term effect of (combined) exposure of AFB1 and FB1
398 on the cellular energy profiles, including glycolysis and mitochondrial respiration pathways, in HepG2
399 cells. This was accomplished by applying relevant doses and combinations of both mycotoxins in
400 which the low level of exposure or treatment is matching with average of urinary biomarkers of AFB1
401 (0.5 µg/mL) and FB1(10 µg/mL) in humans (Meneely et al. 2018). Two more levels of exposure were
402 applied by increasing the applied doses four folds to have a middle exposure scenario and eight folds
403 as high exposure scenario to investigate the potential toxicity. It was found that with advanced
404 respirometry techniques, differential effects between a single mycotoxin treatment compared to the
405 binary mixture became obvious in multiple mitochondrial parameters. Finally, transcriptomics clearly
406 showed distinct effects amongst all different treatments, and differential pathways and genes
407 revealed a particular focus on mitochondrial and proliferation-related mechanisms.

408 ***4.1. Conventional assays confirm earlier findings on cytotoxicity, oxidative stress, and*** 409 ***mitochondrial membrane potential***

410 AFB1, FB1, and their binary mixture (MIX) individually caused cytotoxic effects, ROS generation, and
411 MMP disruption in HepG2 cells, and MIX shows a higher toxic effect for these cytotoxicity endpoints.
412 It is presumed that MIX may aggravate mitochondrial dysfunction, resulting in an increase in ROS
413 generation and induction in MMP disruption. Previous research elucidated the biochemical principles
414 that drive mitochondrial respiration, including the tricarboxylic acid (TCA) cycle and fatty acid β-
415 oxidation in the mitochondrial matrix, that generate electron donors to fuel respiration, ETC
416 complexes, and ATP synthase in the inner mitochondrial membrane (IMM) carrying out oxidative
417 phosphorylation (Vyas et al. 2016). MMP is generated by proton pumps (complex I, III, and IV)
418 through ETC (Zorova et al. 2018). ROS is generated by incomplete electron transfer through ETC
419 complexes I and II resulting in O²⁻ production in the mitochondrial matrix, while an electron leak at
420 complex III generates O²⁻ in both matrix and intermembrane space (Feissner et al. 2009). However,
421 when comparing the effects of AFB1/FB1 and MIX in each applied condition, MIX did not significantly
422 modify cytotoxicity endpoints compared to the individual toxins (ROS and MMP), which may be
423 caused by the different cytotoxicity-related mode-of-action of AFB1 and FB1 in HepG2 cells. Indeed,
424 the toxicology of AFB1 is intimately linked with its biotransformation to the highly reactive AFB1-
425 exo28,9-epoxide (AFBO), which produces direct genotoxicity through the formation of adducts with
426 the DNA, and to a lesser extent the induction of oxidative stress, which is responsible (probably
427 among other causes) for the indirect genotoxicity of AFB1 (Zhu et al. 2021). This mode of action was
428 confirmed with the transcriptomics outcomes, in which AFB1-containing treatments involve DNA

429 damage pathways. On the other hand, FB1 could cause liver toxicity and the most recognized
430 mechanism of action is the disruption of sphingolipid metabolism by inhibiting the ceramide synthase
431 enzyme (Abdul and Chuturgoon 2021).

432 ***4.2. Respirometry reveals interactions between mycotoxins at the level of the*** 433 ***mitochondria***

434 To investigate whether the biological processes such as total ATP production, glycolytic and
435 mitochondrial function are affected by the AFB1/FB1 and MIX, their cellular rates using the Seahorse
436 XF96 instrument were analyzed. The main metabolic routes contributing to energy homeostasis are
437 glycolysis and OXPHOS, which couple the breakdown of nutrients such as glucose, amino acids, and
438 fatty acids to ATP production (Fox et al. 2005). These two pathways also play a pivotal role in redox
439 homeostasis since they contribute to the reducing power required for anabolic processes (Fox et al.
440 2005). The Seahorse XF Real-Time ATP Rate Assay allows the calculation of the mitochondrial and
441 glycolytic ATP production rates, which provides a new dynamic and quantitative insight into cellular
442 bioenergetics by providing a real-time measurement of oxygen production as a proxy for respiration,
443 and lactate secretion as a proxy for glycolysis. The Seahorse XF Glycolysis Stress Test and
444 Mitochondrial Stress Test protocols dissect the glycolytic and respiratory fluxes components into
445 basal, maximal, and reserve (spare) glycolytic or respiratory capacity through the consecutive
446 addition of the stressors such as oligomycin, FCCP, and rotenone in HepG2 cells, whose optimization
447 is reported in **Figure 2, 3, and 4**.

448 AFB1, FB1, and MIX individually disrupted ATP production by glycolysis and mitochondrial respiration
449 or OXPHOS, which is in line with the cytotoxicity data. Interestingly, the MIX condition showed a
450 higher interference with total ATP production metabolism in HepG2 cells compared to the single
451 mycotoxin treatments. In addition, MIX shifted the fraction of ATP production between OXPHOS and
452 glycolysis from 43 %/57 % to 67 %/33 % under high condition, thereby indicating a particular
453 decrease in glycolysis. Generally, cellular metabolism consumes energy of which 70 % is supplied by
454 OXPHOS, although cell type type-dependent differences are reported (Zheng 2012). As HepG2 cells
455 have a cancer-derived origin, energy metabolism and glucose and glutamine uptake are different
456 compared to normal tissues and display a high rate of glycolysis (Zheng 2012). Due to their different
457 origin and differentiation, glycolysis contributes to most of ATP but does not generally exceed 50–60 %
458 in cancer cells (Zu and Guppy 2004). Therefore, according to our data, it is inferred that combined
459 AFB1 and FB1 could suppress energy metabolism and change metabolic phenotype to adapt to
460 microenvironmental changes, which may result in a selective advantage for HepG2 cells to survive
461 under an unfavorable environment (Marusyk and Polyak 2010). Tumor cell proliferation requires

462 sufficient metabolic flux through the pentose phosphate pathway (PPP) to meet the demand for bio-
463 synthetic precursors and to increase protection against oxidative stress, which in turn requires
464 upregulation of substrate flow through glycolysis. This metabolic poise is often coupled with a shift in
465 ATP production from mitochondrial OXPHOS to substrate-level phosphorylation (Skolik et al. 2021).
466 The PPP branches from glycolysis at the first committed step of glucose metabolism, which is
467 catalyzed by hexokinase and consumes glucose-6-phosphate (G6P) as a primary substrate. It is
468 required for the synthesis of ribonucleotides and is a major source of NADPH, which is required for
469 and consumed during fatty acid synthesis and the scavenging of ROS (Skolik et al. 2021). Therefore,
470 the PPP plays a pivotal role in helping glycolytic cancer cells to meet their anabolic demands and
471 combat oxidative stress (Patra and Hay 2014). In the PPP, Glucose-6-phosphate dehydrogenase
472 (G6PD) is an enzyme that catalyzes the first reaction, providing reducing power to all cells in the form
473 of NADPH (Patra and Hay 2014). Therefore, the damage of G6PD may hinder or slow the supply of
474 energy through glycolysis. In our study, it is shown that the fraction of total ATP production started
475 to be shifted in HepG2 cell exposure to middle concentration of AFB1, and then there is a significant
476 shift in HepG2 cell exposure with all high concentrations of MIX. It is hypothesized that AFB1 may
477 reduce the G6PD activity to inhibit glycolysis to produce ATP, which leads to this shift of ATP in
478 HepG2 cells. Raafat et al. have reported that AFB1 exposure is associated with the evident decline in
479 the activity of G6PD enzyme (Raafat et al. 2021). In addition, Liu et al. also mentioned that there may
480 be a novel association of G6PD activity with AFB1-related xenobiotic metabolism (Lin et al. 2013).
481 These previous studies could support our conjecture that AFB1 may reduce the G6PD activity. Our
482 previous studies showed that other microbial toxins, namely *Bacillus cereus* emetic toxin cereulide
483 induces toxicity, which relies on the mitochondrial dysfunction in HepG2 cells. Oxygen consumption
484 rate analyses and the bioenergetics assessment with Seahorse XF analyzer showed measurable
485 mitochondrial impairment at doses of cereulide even lower than here used AFB1 and FB1. Observed
486 mitochondrial dysfunction was greatly reflected in reduction of maximal cell respiration.

487 When considering the specific glycolytic and mitochondrial parameters individually, it was observed
488 that AFB1, FB1, and MIX can significantly inhibit HepG2 cells to produce ATP in both pathways.
489 Especially upon exposure to high mycotoxin concentrations, MIX showed a significant decrease in
490 mitochondrial respiration with all mitochondrial parameters (basal respiration, maximal respiration,
491 ATP production, proton leak, spare respiration capacity, and non-mitochondrial respiration) in HepG2
492 cells compared to only-AFB1/-FB1, while no significance in glycolysis parameters were observed
493 between MIX and single. A decrease in the ATP-linked OCR may indicate a low ATP demand, a lack of
494 substrate availability, and/or severe damage to OXPHOS. The remaining rate of mitochondrial
495 respiration is defined as the proton leak, and consist of protons transported through the

496 mitochondrial membrane during electron transport, that result in oxygen consumption but not ATP
497 production. The spare respiratory capacity (SRC) characterizes the mitochondrial capacity to meet
498 extra energy requirements, beyond the basal level, in response to acute cellular stress or heavy
499 workload and thereby avoiding an ATP crisis, and can be viewed as a determination of mitochondrial
500 fitness, a reflection of “healthy” mitochondria (Marchetti et al. 2020). When cells are subjected to
501 stress, the energy demand increases, with more ATP required to maintain cellular functions
502 (Yamamoto et al. 2016). Our results demonstrated that the combination of AFB1 and FB1 probably
503 led to a significant interaction by causing more disruption of the mitochondrial metabolism
504 resulting in apoptosis (involving complex I-V). As a mode of action, AFB1 exposure can also cause
505 hepatotoxicity at the DNA level, which is accompanied by several metabolic changes including cell
506 membrane metabolism, glycolysis, and TCA cycle functioning, and mainly cause oxidative-stress-
507 mediated impairments of mitochondria functions (Zhang et al., 2011; Zhou et al., 2021). In line with
508 previous research, AFB1 impairs mitochondrial respiration, causes MMP loss, reduces ATP content,
509 and inhibits the function of mitochondrial complexes I-IV (Chen et al. 2022; Xu et al. 2021). Similarly,
510 FB1 is involved in mitochondrial dysfunction by inhibiting ETC in mitochondrial respiration (Chen et al.
511 2022; Sheik Abdul and Marnewick 2020). Therefore, AFB1 and FB1 could disrupt mitochondrial
512 respiration by ETC, which could be the reason that the mixture of AFB1 and FB1 worsened the
513 mitochondrial dysfunction and showed a significant interaction in the disruption of the mitochondrial
514 metabolism. As mitochondrial respiration is affected in many pathologic conditions such as hypoxia
515 and intoxications, the impaired electron transport chain could emit additional p53-inducing signals
516 and thereby contribute to cell damage (Khutornenko et al. 2010). Our transcriptomic results and
517 literature report that AFB1 and FB1 increase p53 expression, which could be another reason for a
518 significant interaction between AFB1 and FB1 on mitochondria damage (Cao et al. 2022; Molina-
519 Pintor et al. 2022).

520 ***4.3. Transcriptomics reveals interactions between both mycotoxins at the level of*** 521 ***mitochondrial functioning and apoptosis***

522 Both metabolic flux measurements from seahorse assays and RNA sequence analysis of AFB1, FB1,
523 and MIX in HepG2 cells indicated mode-of-actions related to cell death, apoptosis, or mitochondrial
524 dysfunction. Interestingly, it was observed that MIX has more similar DEGs with FB1 than with AFB1,
525 thereby suggesting that FB1 dictates the combined response more than AFB1. Nevertheless,
526 compared to AFB1 and FB1 together, MIX could upregulate 72 DEGs (CPLX2, DDX46, ABCC11, SARDH,
527 and CYP24A1 genes: related to mitochondrial metabolism) and downregulate 10 DEGs (RFX2 gene:
528 DNA-binding protein; CD274 gene: programmed cell death), which suggests that AFB1 and FB1 may
529 co-regulate the expression of some genes resulting in a significant interaction. Our results showed

530 that the p53 pathway is one of the co-regulated signaling pathways by AFB1 and FB1, and is related
531 to mitochondrial dysfunction resulting in apoptosis. The p53 pathway is a major orchestrator of the
532 cellular response to a broad array of stress types by regulating mitochondrial apoptosis, DNA repair,
533 and genetic stability, and participates directly in the intrinsic apoptosis pathway by interacting with
534 the multidomain members of the Bcl-2 family to induce mitochondrial dysfunction (Vaseva and Moll
535 2009). This system is essential in humans for genome integrity, DNA repair, and apoptosis (Bernstein
536 et al. 2002).

537 In apoptosis, the stabilization and activation of p53 lead to programmed cell death (Yu et al., 2009),
538 where p53 directly upregulates the expression of cell surface death receptors proteins such as
539 Fas/APO1 and KILLER/DR5 (Burns and El-Deiry 1999). Cytoplasmic pro-apoptotic proteins like PIDD
540 and Bid are also thought to be the putative target of p53 (Sax and El-Deiry 2003). In addition,
541 mitochondrial pro-apoptotic proteins such as Bax, Bak, PUMA, and NOXA are also regulated by p53
542 (Oda et al. 2000; Wei et al. 2001; Yu et al. 2003). In this study, Fas, DR5, PUMA, Noxa, and PIGs genes
543 were significantly downregulated by MIX compared to single FB1 exposure, which could be
544 associated with mitochondrial dysfunction. It also has shown that MIX significantly upregulated p53
545 gene and downregulated Cx I, Cx II, Cx III, and Cx IV genes comparing single FB1 exposure in the p53
546 signaling pathway, which could be the reason for a significant interaction between AFB1 and FB1 on
547 mitochondrial damage. As mitochondrial respiration is affected in many pathologic conditions such
548 as intoxications, the impaired ETC could emit additional p53-inducing signals and thereby contribute
549 to tissue damage (Khutornenko et al. 2010). It is also reported that a strong p53 response is induced
550 specifically after inhibition of the mitochondrial cytochrome bc1 (the electron transport chain
551 complex III). Accumulation of p53 in the mitochondria is observed in animal and cell culture models
552 and is associated with mitochondrial depolarization and mitochondrial complex IV inactivity
553 (Marchenko and Moll 2014). Saleem et al. also mentioned that lower complex IV activity and several
554 impaired indexes of mitochondrial function are related to p53 (Saleem et al. 2015). AFB1 and FB1
555 individually affected the p53 and complexes, which could result in the MIX significantly upregulated
556 p53 gene and downregulated Cx I, Cx II, Cx III, and Cx IV genes resulting in the significant inhibition
557 interaction on mitochondrial respiration. As reported in the literature, HepG2 cells exposed to either
558 AFB1 or FB1 showed a higher abundance of p53 (Budin et al. 2021; Li et al. 2021). Moreover, Du et al
559 have shown that when AFB1 and FB1 were combined, a higher optical density of p53 was observed
560 by immunohistochemical analysis, and they hypothesized that there could be an interaction between
561 AFB1 and FB1 in inducing HepG2 cell apoptosis (Du et al. 2017). This finding is consistent with our
562 results as in the current work MIX also significantly upregulated p53.

563 It has been verified that AFB1 inhibits mitochondrial complexes I-IV activities and FB1 inhibits
564 mitochondrial complex I by decreasing complex sphingolipids (Huang et al. 2020). This is also in a line
565 with our results, where MIX resulted in a significant downregulation of Cx I, Cx II, Cx III, and Cx IV
566 genes. These genes are major mitochondria respiratory complexes in ETC, and linked to cytochrome c
567 (CytC) inducing apoptosis. CytC, a role in cell apoptosis in p53 pathway, is released into the cytosol,
568 and then the protein binds to Apaf-1, activates CASP9, and triggers an enzymatic cascade leading to
569 cell death (Schuler et al. 2000). In our study, the expression of CytC, Apaf-1, CASP9, and CASP3 genes
570 was decreased by MIX compared to FB1. The release of CytC from mitochondria is a central event in
571 the death receptor-independent, “intrinsic,” apoptotic pathway (Desagher and Martinou 2000). CytC
572 is essential for the assembly and respiratory function of the enzyme complex, and the lack of CytC
573 decreases the stability of complex IV, reduces electron transport complex III activity, and modifies
574 redox metabolism (Welchen et al. 2012). CytC together with ATP and Apaf-1 facilitates activation by
575 CASP9 of the effector caspases CASP3 (Slee et al. 1999), which then cleaves their substrates, finally
576 leading to the apoptotic cell death. This complex of CytC, Apaf-1 and CASP9 is commonly referred to
577 as the apoptosome (Bratton et al. 2001). The reduced form of CytC also binds less to anions and
578 binds less tightly to negatively charged membranes. This could be the reason for a significant
579 interaction between AFB1 and FB1 on mitochondria dysfunction and HepG2 cell apoptosis by
580 disrupting the mitochondrial complexes and CytC in p53 pathway.

581 DNA repair is another system in the p53 pathway. The stabilization and activation of p53 lead to cell
582 cycle arrest by increasing GADD45 (Jin et al. 2002), initiating DNA repair through p53R2 and p48
583 (Tanaka et al. 2000). Cells that are defective in DNA repair tend to accumulate excess DNA damage.
584 In addition, cells defective in apoptosis tend to survive even with DNA damage, and the subsequent
585 DNA replication during cell division may cause persistent mutations leading to carcinogenesis
586 (Bernstein et al. 2002). Normally, DNA damage is repaired by base excision repair (BER) by
587 mitochondrial enzymes. Mitochondrial DNA comprises 0.1-1.0 % of the total DNA in most
588 mammalian cells (Singh et al., 1992). Mitochondrial DNA has been proposed to be involved in
589 carcinogenesis because of its high susceptibility to mutations and limited repair mechanisms in
590 comparison to genomic DNA (Penta et al. 2001). Mitochondrial DNA damage, if not repaired, leads to
591 disruption of the ETC and mitochondrial dysfunction (Mandavilli et al. 2002). In general, the energy-
592 demanding process of DNA repair is the proper utilization of the available ATP in the cell which is
593 provided by the mitochondria (Bernstein et al. 2002). Therefore, mitochondrial DNA repair plays a
594 central role in maintaining (energy) homeostasis in the cell. In our study, P48, p53R2, Gadd45, and
595 Sestrins genes were significantly downregulated by MIX compared to FB1 treatment in HepG2 cells.

596 This suggests that the combination of AFB1 and FB1 could have a significant inhibition interaction on
597 the DNA repair system and thus cell homeostasis.

598 Our study also shows that AFB1, FB1, and MIX disrupted HepG2 cell proliferation, by means of E2F
599 targets, G2M checkpoint, mitotic spindle, MYC targets, and p53 pathway. Deregulated cell
600 proliferation could propel the tumor cell and its progeny into uncontrolled expansion and invasion
601 beneath the complexity and idiopathy of every cancer. Neoplastic progression could be further
602 supported by the deregulated cell proliferation that is, together with the obligate compensatory
603 suppression of apoptosis, needed to support it (Evan and Vousden 2001). Previous studies have
604 illustrated that individual AFB1 and FB1 had an ability to induce proliferation to increase apoptosis
605 (Singh and Kang 2017; Zhou et al. 2019). Therefore, we speculate that the combination of AFB1 and
606 FB1 may deregulate proliferation, as a result, triggering apoptosis.

607 **5. Conclusion**

608 The cytotoxicity of AFB1 and FB1 to HepG2 cells has been examined from cytotoxicity endpoints (cell
609 viability, ROS generation, and MMP disruption), total ATP production, glycolytic, mitochondrial
610 function, and gene expression in the cell apoptosis process. The combined exposure of both
611 mycotoxins induced more inhibitory effect on the cellular viability, an increase in the ROS production,
612 and a disruption of MMP. Respirometry and transcriptomics demonstrated a significant interaction
613 between AFB1 and FB1 in pathways related to mitochondrial dysfunction and apoptosis, which is
614 most probably triggered by the p53 pathway and mitochondrial complex Cx I-IV genes. In addition,
615 AFB1 and FB1 affected DNA repair and induce cell proliferation in HepG2 cells in a possible
616 synergistic nature, because of their different targets in cell apoptosis.

617 **CRedit authorship contribution statement**

618 **Xiangrong Chen:** Conceptualization, Methodology, Validation, Formal analysis, Investigation,
619 Resources, Data curation, Writing – original draft. **Mohamed F. Abdallah:** Formal analysis, Data
620 curation, Writing - Review & Editing. **Charlotte Grootaert:** Conceptualization, Validation, Data
621 curation, Writing - Review & Editing. **Filip Van Nieuwerburgh:** Data curation, Methodology, Writing -
622 Review & Editing. **Andreja Rajkovic:** Conceptualization, Methodology, Project administration,
623 Funding acquisition, Writing – review & editing, Supervision.

624 **Declarations of competing interest**

625 The authors declare that they have no known competing financial interests or personal relationships
626 that could have appeared to influence the work reported in this paper.

627 **Funding**

628 This work was conducted within the Horizon 2020 IMPTOX project (www.imptox.eu), funded by the
629 European Union's Horizon 2020 research and innovation program under the grant agreement No
630 [965173](#), Research Foundation Flanders research grant 1506419N given to AR, Ghent University
631 Special research Fund grant given BOF20/BAS/120 to AR for the purchase of Seahorse XF analyzer
632 and China Scholarship Council (CSC) for providing X.C. (File No. 201806170042) with a full personal
633 (not including bench fee) Ph.D. scholarship.

634 **Acknowledgments**

635 The authors wish to thank China Scholarship Council (CSC) for providing X.C. with a full personal (not
636 including bench fee) Ph.D. scholarship (File No. 201806170042) to study at Ghent University, Belgium.
637 M.F.A is supported by the Ghent University Special Research Fund (BOF) postdoc mandate with grant
638 number BOF20/PDO/032. Authors and AR in particular express gratitude to European Commission
639 for the received funding for this research performed as part of ImpTox project (grant agreement No
640 [965173](#)), Research Foundation Flanders for the Research grant provided to AR (1506419N), and
641 Ghent University Special Research Fund given to AR for purchase of Seahorse XF analyzer
642 (BOF20/BAS/120). Authors thank Ghent University, and their respective Faculties and Departments
643 for team work, support and general infrastructure.

644 **Data availability**

645 All data generated or analyzed in this study that are relevant to the results presented in this article
646 are included in the article.

647 **References**

- 648 Abdul NS, Chuturgoon AA. Fumonisin B1 regulates LDL receptor and ABCA1 expression in an LXR
649 dependent mechanism in liver (HepG2) cells. *Toxicol. Pergamon*; 2021 Jan 30;190:58–64.
- 650 Alam S, Nisa S, Daud S. *Mycotoxins in Environment and Its Health Implications*. Springer, Cham; 2022
651 [cited 2022 Nov 7]. p. 289–318. Available from: [https://link.springer.com/chapter/10.1007/978-3-](https://link.springer.com/chapter/10.1007/978-3-030-96523-5_12)
652 [030-96523-5_12](https://link.springer.com/chapter/10.1007/978-3-030-96523-5_12)
- 653 Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five
654 major DNA repair pathways: Fail-safe protection against carcinogenesis. *Mutat. Res. - Rev. Mutat.*
655 *Res. Elsevier*; 2002. p. 145–78.
- 656 Bratton SB, Walker G, Srinivasula SM, Sun XM, Butterworth M, Alnemri ES, et al. Recruitment,

- 657 activation and retention of caspases-9 and-3 by Apaf-1 apoptosome and associated XIAP complexes.
658 EMBO J. [Internet]. John Wiley & Sons, Ltd; 2001 Mar 1 [cited 2022 Aug 2];20(5):998–1009. Available
659 from: <https://onlinelibrary.wiley.com/doi/full/10.1093/emboj/20.5.998>
- 660 Budin C, Man HY, Al-Ayoubi C, Puel S, van Vugt-Lussenburg BMA, Brouwer A, et al. Versicolorin A
661 enhances the genotoxicity of aflatoxin B1 in human liver cells by inducing the transactivation of the
662 Ah-receptor. *Food Chem. Toxicol.* Pergamon; 2021 Jul 1;153:112258.
- 663 Burns TF, El-Deiry WS. The p53 pathway and apoptosis. *J. Cell. Physiol.* 1999. p. 231–9.
- 664 Cao W, Yu P, Yang KP, Cao D. Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative
665 stress and cancer development [Internet]. *Toxicol. Mech. Methods.* Taylor & Francis; 2022 [cited
666 2022 Jul 15]. p. 395–419. Available from:
667 <https://www.tandfonline.com/doi/abs/10.1080/15376516.2021.2021339>
- 668 Chen X, Abdallah MF, Grootaert C, Rajkovic A. Bioenergetic Status of the Intestinal and Hepatic Cells
669 after Short Term Exposure to Fumonisin B1 and Aflatoxin B1. *Int. J. Mol. Sci.* [Internet].
670 Multidisciplinary Digital Publishing Institute; 2022 Jun 22 [cited 2022 Jul 15];23(13):6945. Available
671 from: <https://www.mdpi.com/1422-0067/23/13/6945/htm>
- 672 Chen X, Landschoot S, Detavernier C, De Saeger S, Rajkovic A, Audenaert K. Cross-talk between
673 *Fusarium verticillioides* and *Aspergillus flavus* in vitro and in planta. *Mycotoxin Res.* [Internet].
674 Springer; 2021 Jun 14 [cited 2021 Sep 20];37(3):229–40. Available from:
675 <https://link.springer.com/article/10.1007/s12550-021-00435-x>
- 676 Decler M, Jovanovic J, Vakula A, Udovicki B, Agoua R-SSEK, Madder A, et al. Oxygen consumption
677 rate analysis of mitochondrial dysfunction caused by *Bacillus cereus cereulide* in Caco-2 and HepG2
678 cells. *Toxins (Basel)*. [Internet]. Multidisciplinary Digital Publishing Institute; 2018 Jul 2 [cited 2021
679 Sep 28];10(7):266. Available from: <https://www.mdpi.com/2072-6651/10/7/266/htm>
- 680 Degroote H, Lefere S, Vandierendonck A, Vanderborght B, Meese T, Nieuwerburgh F Van, et al.
681 Characterization of the inflammatory microenvironment and hepatic macrophage subsets in
682 experimental hepatocellular carcinoma models. *Oncotarget* [Internet]. Impact Journals, LLC; 2021
683 Mar 3 [cited 2022 Nov 21];12(6):562–77. Available from: [/pmc/articles/PMC7984829/](https://pmc/articles/PMC7984829/)
- 684 Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. *Trends Cell Biol.*
685 Elsevier Current Trends; 2000. p. 369–77.
- 686 Du M, Liu Y, Zhang G. Interaction of aflatoxin B1 and fumonisin B1 in HepG2 cell apoptosis. *Food*
687 *Biosci.* Elsevier; 2017 Dec 1;20:131–40.

- 688 Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer [Internet]. Nature. Nature
689 Publishing Group; 2001 [cited 2022 Jul 27]. p. 342–8. Available from:
690 <https://www.nature.com/articles/35077213>
- 691 Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca²⁺ and ROS.
692 Front. Biosci. [Internet]. NIH Public Access; 2009 Jan 1 [cited 2022 May 13];14(4):1197–218. Available
693 from: </pmc/articles/PMC2683671/>
- 694 Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: Energy metabolism and the T-cell
695 response [Internet]. Nat. Rev. Immunol. Nature Publishing Group; 2005 [cited 2022 Aug 1]. p. 844–52.
696 Available from: <https://www.nature.com/articles/nri1710>
- 697 Huang W, Cao Z, Yao Q, Ji Q, Zhang J, Li Y. Mitochondrial damage are involved in Aflatoxin B1-induced
698 testicular damage and spermatogenesis disorder in mice. Sci. Total Environ. Elsevier; 2020 Jan
699 20;701:135077.
- 700 IARC. Aflatoxin: Scientific Background, Control, and Implications - Google Books [Internet]. IARC
701 (International Agency Res. Cancer). 2012 [cited 2022 Jun 29]. p. 225–48. Available from:
702 https://books.google.be/books?hl=en&lr=&id=0rhSiCG3li4C&oi=fnd&pg=PR1&ots=oOPlcU9Dlk&sig=LWOnhjrQ4qnwU-vWmpcDGWYZf1g&redir_esc=y#v=onepage&q&f=false
- 704 Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, et al. GADD45-induced cell cycle G2-M arrest
705 associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity.
706 Oncogene [Internet]. Nature Publishing Group; 2002 Dec 16 [cited 2022 Aug 2];21(57):8696–704.
707 Available from: <https://www.nature.com/articles/1206034>
- 708 Khutorenko AA, Roudko V V., Chernyak B V., Vartapetian AB, Chumakov PM, Evstafieva AG.
709 Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc. Natl. Acad. Sci. U. S.
710 A. [Internet]. 2010 Jul 20 [cited 2022 Jul 15];107(29):12828–33. Available from:
711 www.pnas.org/lookup/suppl/
- 712 Li C, Liu X, Wu J, Ji X, Xu Q. Research progress in toxicological effects and mechanism of aflatoxin B1
713 toxin. PeerJ [Internet]. PeerJ Inc.; 2022 [cited 2022 Sep 11];10. Available from:
714 </pmc/articles/PMC9357370/>
- 715 Li Q, Yuan Q, Wang T, Zhan Y, Yang L, Fan Y, et al. Fumonisin B1 inhibits cell proliferation and
716 decreases barrier function of swine umbilical vein endothelial cells. Toxins (Basel). 2021;13(12).
- 717 Lin HR, Wu CC, Wu YH, Hsu CW, Cheng ML, Chiu DTY. Proteome-wide dysregulation by glucose-6-
718 phosphate dehydrogenase (G6PD) reveals a novel protective role for G6PD in aflatoxin B1-mediated

- 719 cytotoxicity. *J. Proteome Res.* [Internet]. 2013 [cited 2022 Sep 27];12(7):3434–48. Available from:
720 <http://www.ebi.ac.uk/>
- 721 Mandavilli BS, Santos JH, Van Houten B. Mitochondrial DNA repair and aging. *Mutat. Res. - Fundam.*
722 *Mol. Mech. Mutagen.* Elsevier; 2002 Nov 30;509(1–2):127–51.
- 723 Marchenko ND, Moll UM. Mitochondrial death functions of p53. *Mol. Cell. Oncol.* 2014.
- 724 Marchetti P, Fovez Q, Germain N, Khamari R, Kluza J. Mitochondrial spare respiratory capacity:
725 Mechanisms, regulation, and significance in non-transformed and cancer cells [Internet]. *FASEB J.*
726 John Wiley & Sons, Ltd; 2020 [cited 2021 Nov 5]. p. 13106–24. Available from:
727 <https://onlinelibrary.wiley.com/doi/full/10.1096/fj.202000767R>
- 728 Marusyk A, Polyak K. Tumor heterogeneity: Causes and consequences. *Biochim. Biophys. Acta - Rev.*
729 *Cancer.* Elsevier; 2010. p. 105–17.
- 730 Meneely JP, Hajšlová J, Krska R, Elliott CT. Assessing the combined toxicity of the natural toxins,
731 aflatoxin B1, fumonisin B1 and microcystin-LR by high content analysis. *Food Chem. Toxicol.*
732 Pergamon; 2018 Nov 1;121:527–40.
- 733 Molina-Pintor IB, Rojas-García AE, Medina-Díaz IM, Barrón-Vivanco BS, Bernal-Hernández YY, Ortega-
734 Cervantes L, et al. An update on genotoxic and epigenetic studies of fumonisin B 1. *World Mycotoxin*
735 *J.* Wageningen Academic Publishers; 2022 Feb 22;15(1):57–72.
- 736 Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the
737 Bcl-2 family and candidate mediator of p53-induced apoptosis. *Science (80-.).* [Internet]. American
738 Association for the Advancement of Science; 2000 May 12 [cited 2022 Aug 2];288(5468):1053–8.
739 Available from: <https://www.science.org/doi/10.1126/science.288.5468.1053>
- 740 Palumbo R, Crisci A, Venâncio A, Abrahantes JC, Dorne J Lou, Battilani P, et al. Occurrence and co-
741 occurrence of mycotoxins in cereal-based feed and food. *Microorganisms* [Internet]. Multidisciplinary
742 Digital Publishing Institute; 2020 Jan 3 [cited 2022 Mar 1];8(1):74. Available from:
743 <https://www.mdpi.com/2076-2607/8/1/74/html>
- 744 Patra KC, Hay N. The pentose phosphate pathway and cancer. *Trends Biochem. Sci.* Elsevier Current
745 Trends; 2014. p. 347–54.
- 746 Penta JS, Johnson FM, Wachsman JT, Copeland WC. Mitochondrial DNA in human malignancy. *Mutat.*
747 *Res. - Rev. Mutat. Res.* Elsevier; 2001. p. 119–33.
- 748 Prakash C, Chhikara S, Kumar V. Mitochondrial Dysfunction in Arsenic-Induced Hepatotoxicity:

- 749 Pathogenic and Therapeutic Implications [Internet]. Biol. Trace Elem. Res. Humana Press Inc.; 2022
750 [cited 2022 Nov 7]. p. 261–70. Available from: [https://link.springer.com/article/10.1007/s12011-021-](https://link.springer.com/article/10.1007/s12011-021-02624-2)
751 02624-2
- 752 Raafat N, Emam WA, Gharib AF, Nafea OE, Zakaria M. Assessment of serum aflatoxin B1 levels in
753 neonatal jaundice with glucose-6-phosphate dehydrogenase deficiency: a preliminary study.
754 Mycotoxin Res. [Internet]. Springer Science and Business Media Deutschland GmbH; 2021 Feb 1
755 [cited 2022 Sep 27];37(1):109–16. Available from: [https://link.springer.com/article/10.1007/s12550-](https://link.springer.com/article/10.1007/s12550-020-00421-9)
756 020-00421-9
- 757 Saleem A, Iqbal S, Zhang Y, Hood DA. Effect of p53 on mitochondrial morphology, import, and
758 assembly in skeletal muscle. Am. J. Physiol. - Cell Physiol. 2015;308(4):C319–29.
- 759 Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ. 2003. p. 413–7.
- 760 Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase
761 activation through mitochondrial cytochrome c release. J. Biol. Chem. [Internet]. Elsevier; 2000 Mar
762 10 [cited 2022 Aug 2];275(10):7337–42. Available from:
763 <http://www.jbc.org/article/S0021925818304290/fulltext>
- 764 Sheik Abdul N, Marnewick JL. Fumonisin B1-induced mitochondrial toxicity and hepatoprotective
765 potential of rooibos: An update [Internet]. J. Appl. Toxicol. John Wiley & Sons, Ltd; 2020 [cited 2022
766 May 16]. p. 1602–13. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/jat.4036>
- 767 Singh G, Sharkey SM, Moorehead R. Mitochondrial DNA damage by anticancer agents. Pharmacol.
768 Ther. Pergamon; 1992. p. 217–30.
- 769 Singh MP, Kang SC. Endoplasmic reticulum stress-mediated autophagy activation attenuates
770 fumonisin B1 induced hepatotoxicity in vitro and in vivo. Food Chem. Toxicol. Pergamon; 2017 Dec
771 1;110:371–82.
- 772 Singto T, Tassaneeyakul W, Porasuphatana S. Protective effects of purple waxy corn on aflatoxin B1-
773 induced oxidative stress and micronucleus in HepG2 cells. Indian J. Pharm. Sci. [Internet]. OMICS
774 International; 2020 Sep 30 [cited 2022 Feb 28];82(3):506–13. Available from:
775 [https://www.ijpsonline.com/articles/protective-effects-of-purple-waxy-corn-on-aflatoxin-b1induced-](https://www.ijpsonline.com/articles/protective-effects-of-purple-waxy-corn-on-aflatoxin-b1induced-oxidative-stress-and-micronucleus-in-hepg2-cells-3952.html)
776 oxidative-stress-and-micronucleus-in-hepg2-cells-3952.html
- 777 Skolik RA, Solocinski J, Konkle ME, Chakraborty N, Menze MA. Global changes to HepG2 cell
778 metabolism in response to galactose treatment. Am. J. Physiol. - Cell Physiol. [Internet]. American
779 Physiological Society; 2021 May 1 [cited 2022 Sep 27];320(5):C778–93. Available from:

- 780 www.ajpcell.org
- 781 Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-
782 initiated caspase cascade: Hierarchical activation of caspases-2,-3,-6,-7,-8, and -10 in a caspase-9-
783 dependent manner. *J. Cell Biol.* [Internet]. The Rockefeller University Press; 1999 Jan 25 [cited 2022
784 Aug 2];144(2):281–92. Available from: <http://www.jcb.org>
- 785 Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase
786 gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature* [Internet]. Nature
787 Publishing Group; 2000 Mar 2 [cited 2022 Aug 2];404(6773):42–9. Available from:
788 <https://www.nature.com/articles/35003506>
- 789 Vaseva A V., Moll UM. The mitochondrial p53 pathway. *Biochim. Biophys. Acta - Bioenerg.* [Internet].
790 Elsevier B.V.; 2009;1787(5):414–20. Available from: <http://dx.doi.org/10.1016/j.bbabi.2008.10.005>
- 791 Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. *Cell.* Cell Press; 2016. p. 555–66.
- 792 Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and
793 BAK: A requisite gateway to mitochondrial dysfunction and death. *Science* (80-.). 2001 Apr
794 27;292(5517):727–30.
- 795 Welchen E, Hildebrandt TM, Lewejohann D, Gonzalez DH, Braun HP. Lack of cytochrome c in
796 Arabidopsis decreases stability of Complex IV and modifies redox metabolism without affecting
797 Complexes I and III. *Biochim. Biophys. Acta - Bioenerg.* Elsevier; 2012 Jul 1;1817(7):990–1001.
- 798 Wu F, Groopman JD, Pestka JJ. Public health impacts of foodborne mycotoxins. *Annu. Rev. Food Sci.*
799 *Technol.* [Internet]. 2014 [cited 2022 Nov 23];5(1):351–72. Available from:
800 <http://food.annualreviews.org>
- 801 Xu F, Li Y, Cao Z, Zhang J, Huang W. AFB1-induced mice liver injury involves mitochondrial
802 dysfunction mediated by mitochondrial biogenesis inhibition. *Ecotoxicol. Environ. Saf. Academic*
803 *Press*; 2021 Jun 15;216:112213.
- 804 Yamamoto H, Morino K, Mengistu L, Ishibashi T, Kiriyaama K, Ikami T, et al. Amla Enhances
805 Mitochondrial Spare Respiratory Capacity by Increasing Mitochondrial Biogenesis and Antioxidant
806 Systems in a Murine Skeletal Muscle Cell Line. *Oxid. Med. Cell. Longev.* [Internet]. Hindawi Limited;
807 2016 [cited 2022 Jul 15];2016. Available from: [/pmc/articles/PMC4909908/](http://pmc/articles/PMC4909908/)
- 808 Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in
809 colorectal cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* [Internet]. Proceedings of the National Academy
810 of Sciences; 2003 Feb 18 [cited 2022 Aug 2];100(4):1931–6. Available from:

- 811 <https://www.pnas.org/doi/abs/10.1073/pnas.2627984100>
- 812 Yu Z, Wang H, Zhang L, Tang A, Zhai Q, Wen J, et al. Both p53-PUMA/NOXA-Bax-mitochondrion and
813 p53-p21cip1 pathways are involved in the CDglyTK-mediated tumor cell suppression. *Biochem.*
814 *Biophys. Res. Commun. Academic Press*; 2009 Sep 4;386(4):607–11.
- 815 Zhang L, Ye Y, An Y, Tian Y, Wang Y, Tang H. Systems responses of rats to aflatoxin B1 exposure
816 revealed with metabonomic changes in multiple biological matrices. *J. Proteome Res.* [Internet].
817 American Chemical Society; 2011 Feb 4 [cited 2022 Jul 15];10(2):614–23. Available from:
818 <https://pubs.acs.org/doi/full/10.1021/pr100792q>
- 819 Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (review) [Internet].
820 *Oncol. Lett. Spandidos Publications*; 2012 [cited 2022 Jul 15]. p. 1151–7. Available from:
821 </pmc/articles/PMC3506713/>
- 822 Zhou J, Tang L, Wang JS. Aflatoxin B1Induces Gut-Inflammation-Associated Fecal Lipidome Changes in
823 F344 Rats. *Toxicol. Sci.* [Internet]. Oxford Academic; 2021 Sep 28 [cited 2022 Jul 15];183(2):363–77.
824 Available from: <https://academic.oup.com/toxsci/article/183/2/363/6343465>
- 825 Zhou R, Liu M, Liang X, Su M, Li R. Clinical features of aflatoxin B1-exposed patients with liver cancer
826 and the molecular mechanism of aflatoxin B1 on liver cancer cells. *Environ. Toxicol. Pharmacol.*
827 Elsevier; 2019 Oct 1;71:103225.
- 828 Zhu Q, Ma Y, Liang J, Wei Z, Li M, Zhang Y, et al. AHR mediates the aflatoxin B1 toxicity associated
829 with hepatocellular carcinoma. *Signal Transduct. Target. Ther.* [Internet]. Nature Publishing Group;
830 2021 Aug 9 [cited 2022 Feb 28];6(1):1–13. Available from: [https://www.nature.com/articles/s41392-](https://www.nature.com/articles/s41392-021-00713-1)
831 [021-00713-1](https://www.nature.com/articles/s41392-021-00713-1)
- 832 Zorova LD, Popkov VA, Plotnikov EY, Silachev DN, Pevzner IB, Jankauskas SS, et al. Mitochondrial
833 membrane potential. *Anal. Biochem. Academic Press*; 2018 Jul 1;552:50–9.
- 834 Zu XL, Guppy M. Cancer metabolism: Facts, fantasy, and fiction. *Biochem. Biophys. Res. Commun.*
835 *Academic Press*; 2004. p. 459–65.
- 836